# A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults

> **NCT05074433** · PHASE3 · TERMINATED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 66 (actual)

## Conditions studied

- Immunocompromised

## Interventions

- **DRUG:** casirivimab+imdevimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05074433
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-10-25
- **Primary completion:** 2022-05-18
- **Final completion:** 2022-05-18
- **Target enrollment:** 66 (ACTUAL)
- **Why stopped:** Emerging SARS-CoV2 variants impacting susceptibility to study drug
- **Last updated:** 2025-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05074433

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05074433, "A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05074433. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*